Google
NRSNW — NEUROSENSE THERAPEUTICS LTD. WARRANT
NRSNW FAQ
What is NRSNW's ROE?
NEUROSENSE THERAPEUTICS LTD. WARRANT reports a Return on Equity (ROE) of 713.14%.
What is NRSNW's dividend yield?
NEUROSENSE THERAPEUTICS LTD. WARRANT offers a dividend yield of 0.00%.
What is NRSNW's Deepscope Quality Score?
Deepscope rates NRSNW's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy NRSNW?
Deepscope's AI Timing Score for NRSNW is 1 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
|
USD 0.20
Price
0.01
(5.74%)
Day Change
|
|
|---|
NRSNW, the overall quality is not good ( Quality = 46) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.20 |
| PBV / Sector |
-4.19 / N/A
|
| Earning Per Share | -0.44 |
| PE / Sector |
N/A / N/A
|
| PEG or PE/Growth / Sector |
N/A / N/A
|
| Average 1M Daily Value |
280.404290000000
|
| Average 1W Daily Value |
863.332920000000
|
| Timing Factors |
|
57% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Building B, Herzliya, Israel, 4672562
Phone: 972 9 799 6183
Website: https://www.neurosense-tx.com
Sector: -
Description: NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
ME vs SECTOR
Click a bubble to view stock details · Bubble size represents market capitalization share
